Details for New Drug Application (NDA): 020647
✉ Email this page to a colleague
NDA 020647 describes ELDEPRYL, which is a drug marketed by Norvium Bioscience and is included in one NDA. Additional details are available on the ELDEPRYL profile page.
The generic ingredient in ELDEPRYL is selegiline hydrochloride. There are seventeen drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the selegiline hydrochloride profile page.
The generic ingredient in ELDEPRYL is selegiline hydrochloride. There are seventeen drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the selegiline hydrochloride profile page.
Summary for 020647
| Tradename: | ELDEPRYL |
| Applicant: | Norvium Bioscience |
| Ingredient: | selegiline hydrochloride |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | CAPSULE;ORAL | Strength | 5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
| Approval Date: | May 15, 1996 | TE: | RLD: | Yes | |||||
Complete Access Available with Subscription
